Liraglutide vs AHK-Cu
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Liraglutide
Liraglutide is a GLP-1 receptor agonist FDA-approved as Victoza for type 2 diabetes and Saxenda for chronic weight management. It was one of the first daily GLP-1 agonists and paved the way for newer weekly options like semaglutide.
Full details →AHK-Cu
AHK-Cu (Copper Tripeptide-3, Alanine-Histidine-Lysine Copper) is a copper peptide similar to GHK-Cu but with different properties. It's used for hair growth and skin rejuvenation applications.
Full details →Side-by-Side Comparison
| Aspect | Liraglutide | AHK-Cu |
|---|---|---|
| Mechanism | Binds to and activates GLP-1 receptors, stimulating insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and reducing appetite through central nervous system effects. | The copper-binding tripeptide stimulates collagen synthesis and may promote hair follicle enlargement. Works similarly to GHK-Cu but may have distinct receptor interactions. |
| Typical Dosage | Saxenda (weight loss): Start 0.6mg daily, increase weekly by 0.6mg to maintenance dose of 3mg daily. Victoza (diabetes): 0.6mg to 1.8mg daily. | Topical: 0.5-2% concentration in serums for skin or scalp applications. Often combined with other growth factors for hair formulations. |
| Administration | Subcutaneous injection once daily at any time, independent of meals. Rotate injection sites. Can be used with oral diabetes medications. | Topical application to skin or scalp. Can be used with microneedling for enhanced penetration. May cause temporary blue-green tint at high concentrations. |
| Side Effects | Nausea, vomiting, diarrhea, constipation, headache, decreased appetite. GI effects typically diminish over time with continued use. | Generally well-tolerated. May cause skin irritation in sensitive individuals. Temporary discoloration possible. |
| Best For |